Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 4, n° 5
pages 561-565 (mai 1981)
Doi : 10.1016/S0190-9622(81)70057-4
Clinical and laboratory study

The effect of photochemotherapy on the cardiovascular system

Susan G. Chappe, M.D. 1, , Henry H. Roenigk, M.D. 1, Albert J. Miller, M.D. 1, Daniel E. Beeaff, M.D. 1, Laada Tyrpin 1
Chicago, IL, USA 

Reprint requests to: Dr. Susan G. Chappe, Northwestern University Medical School, Department of Dermatology, 303 East Chicago Ave., Chicago, IL 60611.

Photochemotherapy, consisting of the oral administration of psoralens plus long-wave ultraviolet radiation (PUVA), involves standing in a warm light cabinet for a prolonged time. This study was done to evaluate the cardiovascular reactions in normal patients and in patients with cardiac disease receiving PUVA therapy. Of forty patients studied, six had cardiovascular disease and sixteen had essential hypertension. Holter monitoring during treatment revealed no significant arrhythmias. All patients had a modest increase in heart rate at the end of PUVA, with a mean increase of 22% of baseline. Blood pressure was not significantly changed, and 12-lead electrocardiograms done in twenty-two of the patients before and after PUVA showed no significant changes. Our patients, including those with cardiovascular disease and hypertension, tolerated the PUVA therapy without significant subjective reactions and without evidence of excessive cardiovascular stress.

The full text of this article is available in PDF format.

* This study was, in part, supported by Northwestern University Medical School Research and Education Fund No. 4253-118.

1  From the Department of Dermatology and the Cardiology Section, Department of Medicine, Northwestern University Medical School.

Top of the page

© 1981  Published by Elsevier Masson SAS.